References
- Zissimopoulos A, Vradelis S, Konialis M, Chadolias D, Bampali A, Constantinidis T, et al. Chromogranin A as a biomarker of disease activity and biologic therapy in inflammatory bowel disease: a prospective observational study. Scand J Gastroenterol 2014;49:942–9.
- Lawrence B, Gustafsson BI, Kidd M, Pavel M, Svejda B, Modlin IM. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 2011;40:111–34.
- Saverymuttu SH, Hodgson HJ, Chadwick VS, Pepys MB. Differing acute phase responses in Crohn’s disease and ulcerative colitis. Gut 1986;27:809–13.
- Onal IK, Beyazit Y, Sener B, Savuk B, Ozer Etik D, Sayilir A, et al. The value of Fecal calprotectin as a marker of intestinal inflammation in patients with ulcerative colitis. Turk J Gastroenterol 2012;23:509–14.
- Sipponen T, Savilahti E, Kolho KL, Nuutinen H, Turunen U, Färkkilä M. Crohn’s disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn’s disease activity index and endoscopic findings. Inflamm Bowel Dis 2008;14:40–6.
- Onal IK, Arhan M, Ozin YO, Tas A, Sezer S, Demirel BT, et al. Efficacy and safety of azathioprine therapy in Turkish patients with inflammatory bowel disease: a retrospective long term follow up study. Turkiye Klinikleri J Med Sci 2011;31:568–74.